These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24793951)

  • 1. Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada.
    Rouleau I; De Serres G; Skowronski DM; Drolet JP; Lemire C; Toth E; Landry M
    Vaccine; 2014 Jun; 32(28):3480-7. PubMed ID: 24793951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine.
    Gagnon R; Primeau MN; Des Roches A; Lemire C; Kagan R; Carr S; Ouakki M; Benoît M; De Serres G;
    J Allergy Clin Immunol; 2010 Aug; 126(2):317-23. PubMed ID: 20579720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine.
    Rouleau I; De Serres G; Drolet JP; Skowronski DM; Ouakki M; Toth E; Landry M; Ménard S; Gagnon R
    Vaccine; 2013 Dec; 31(50):5989-96. PubMed ID: 24144473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec.
    De Wals P; Deceuninck G; Toth E; Boulianne N; Brunet D; Boucher RM; Landry M; De Serres G
    JAMA; 2012 Jul; 308(2):175-81. PubMed ID: 22782419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells.
    Bencharitiwong R; Leonard S; Tsai T; Nowak-Węgrzyn A
    Hum Vaccin Immunother; 2012 Jul; 8(7):863-5. PubMed ID: 22777093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.
    Halsey NA; Griffioen M; Dreskin SC; Dekker CL; Wood R; Sharma D; Jones JF; LaRussa PS; Garner J; Berger M; Proveaux T; Vellozzi C; ; Broder K; Setse R; Pahud B; Hrncir D; Choi H; Sparks R; Williams SE; Engler RJ; Gidudu J; Baxter R; Klein N; Edwards K; Cano M; Kelso JM
    Vaccine; 2013 Dec; 31(51):6107-12. PubMed ID: 24120547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France.
    Dauvilliers Y; Arnulf I; Lecendreux M; Monaca Charley C; Franco P; Drouot X; d'Ortho MP; Launois S; Lignot S; Bourgin P; Nogues B; Rey M; Bayard S; Scholz S; Lavault S; Tubert-Bitter P; Saussier C; Pariente A;
    Brain; 2013 Aug; 136(Pt 8):2486-96. PubMed ID: 23884811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in renal transplant recipients.
    Salles MJ; Sens YA; Malafronte P; Souza JF; Vilas Boas LS; Machado CM
    Transpl Infect Dis; 2012 Dec; 14(6):564-74. PubMed ID: 22882692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of pandemic H1N1 vaccine against influenza-related hospitalization in children.
    Gilca R; Deceuninck G; De Serres G; Boulianne N; Sauvageau C; Quach C; Boucher FD; Skowronski DM
    Pediatrics; 2011 Nov; 128(5):e1084-91. PubMed ID: 21987710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of the monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine against hospitalization in children because of influenza.
    Ortqvist A; Bennet R; Rinder MR; Lindblad H; Eriksson M
    Vaccine; 2012 Aug; 30(39):5699-702. PubMed ID: 22819987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective.
    Tavares F; Delaigle A; Slavin D; Bauchau V; Fries L; Seifert H
    Vaccine; 2011 Aug; 29(37):6402-7. PubMed ID: 21527305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: population-based case-control study.
    Mahmud S; Hammond G; Elliott L; Hilderman T; Kurbis C; Caetano P; Van Caeseele P; Kettner J; Dawood M
    Vaccine; 2011 Oct; 29(45):7975-81. PubMed ID: 21884747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
    Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy.
    Pasternak B; Svanström H; Mølgaard-Nielsen D; Krause TG; Emborg HD; Melbye M; Hviid A
    JAMA; 2012 Jul; 308(2):165-74. PubMed ID: 22782418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: a population-based study in Taiwan.
    Huang WT; Tang FW; Yang SE; Chih YC; Chuang JH
    Vaccine; 2014 Nov; 32(48):6463-8. PubMed ID: 25285884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.
    Skowronski DM; Janjua NZ; De Serres G; Hottes TS; Dickinson JA; Crowcroft N; Kwindt TL; Tang P; Charest H; Fonseca K; Gubbay JB; Bastien N; Li Y; Petric M
    BMJ; 2011 Feb; 342():c7297. PubMed ID: 21292718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic.
    Reynales H; Astudillo P; de Vallière S; Hatz C; Schlagenhauf P; Rath B; Velentgas P; Fariña A; Sales-Carmona V; Groth N
    Vaccine; 2012 Oct; 30(45):6436-43. PubMed ID: 22902681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active surveillance of adverse events following immunization against pandemic influenza A (H1N1) in Korea.
    Choe YJ; Cho H; Song KM; Kim JH; Han OP; Kwon YH; Bae GR; Lee HJ; Lee JK
    Jpn J Infect Dis; 2011; 64(4):297-303. PubMed ID: 21788704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in risk for narcolepsy over time and impact of definition of onset date following vaccination with AS03 adjuvanted pandemic A/H1N1 influenza vaccine (Pandemrix) during the 2009 H1N1 influenza pandemic.
    Granath F; Gedeborg R; Smedje H; Feltelius N
    Pharmacoepidemiol Drug Saf; 2019 Aug; 28(8):1045-1053. PubMed ID: 31062443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.